A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
- Status
- RECRUITING
- Phase
- PHASE1
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
- Status
- UNKNOWN
- Phase
- NA
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Personalized Medicine for Advanced Biliary Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
RP-6306 in Patients With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3